Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 06, 2021 Filed Apr 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 10,000 | $40.95 | $409,500.00 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.60 to 41.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,354 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-21-024893 · doc4.xml · derivative · entry 7 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,396 Underlying: Common Stock · 1,354 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,771 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-024893 · doc4.xml · derivative · entry 6 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 1,771 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,042 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-024893 · doc4.xml · derivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,042 Underlying: Common Stock · 1,042 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 4,167 | $40.00 | $166,680.00 |
DisclosureSEC source: 0001209191-21-024893 · doc4.xml · nonDerivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,036 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,354 | $31.71 | $42,935.34 |
DisclosureSEC source: 0001209191-21-024893 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,771 | $6.55 | $11,600.05 |
DisclosureSEC source: 0001209191-21-024893 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 21:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 1,042 | $7.80 | $8,127.60 |
DisclosureSEC source: 0001209191-21-024893 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,290 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · derivative · entry 12 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,485 Underlying: Common Stock · 5,290 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 1,481 | $38.72 | $57,344.32 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.58 to 38.88, inclusive. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,809 | $38.13 | $145,237.17 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,841 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.54 to 38.51, inclusive. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 5,290 | $6.32 | $33,432.80 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,395 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · derivative · entry 11 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,775 Underlying: Common Stock · 6,395 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 400 | $41.76 | $16,704.00 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.42 to 42.19, inclusive. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 4,175 | $40.33 | $168,377.75 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,760 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.00 to 40.87, inclusive. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 1,820 | $39.43 | $71,762.60 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,935 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.96 to 39.90, inclusive. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,395 | $6.32 | $40,416.40 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 23, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,790 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · derivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,170 Underlying: Common Stock · 7,790 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 23, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 7,790 | $41.93 | $326,634.70 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,360 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.46 to 42.45, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 23, 2021 Filed Mar 26, 2021 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 7,790 | $6.32 | $49,232.80 |
DisclosureSEC source: 0001209191-21-023116 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 19, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 100 | $42.48 | $4,248.00 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 8 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,461 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.48 to 42.50, inclusive. Read SEC document |
| March 19, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 4,900 | $41.96 | $205,604.00 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 7 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,561 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.39 to 42.34, inclusive. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC |
Palaniappan JyotiSVP, Diagnostics, immunoSEQ Dx
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 16,052 | $0.00 Strike: $22.55 | $0.00 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · derivative · entry 5 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,948 Underlying: Common Stock · 16,052 shares Expires 2030-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC |
Palaniappan JyotiSVP, Diagnostics, immunoSEQ Dx
|
SaleCommon Stock | 1,739 | $45.32 | $78,811.48 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 4 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,158 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.63 to 45.54, inclusive. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC |
Palaniappan JyotiSVP, Diagnostics, immunoSEQ Dx
|
SaleCommon Stock | 5,971 | $43.83 | $261,708.93 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 3 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,897 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.63 to 44.53, inclusive. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC |
Palaniappan JyotiSVP, Diagnostics, immunoSEQ Dx
|
SaleCommon Stock | 8,342 | $43.04 | $359,039.68 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 2 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,868 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.60 to 43.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:00 UTC |
Palaniappan JyotiSVP, Diagnostics, immunoSEQ Dx
|
Exercise / conversionCommon Stock | 16,052 | $22.55 | $361,972.60 |
DisclosureSEC source: 0001209191-21-022205 · doc4.xml · nonDerivative · entry 1 Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020. Read SEC document |
| March 18, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 470 | $43.78 | $20,576.60 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,768,461 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.59 to 44.01, inclusive. Read SEC document |
| March 18, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 2,604 | $42.81 | $111,477.24 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 5 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,768,931 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.55 to 43.33, inclusive. Read SEC document |
| March 18, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,926 | $41.90 | $80,699.40 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 4 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,535 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.49 to 42.41, inclusive. Read SEC document |
| March 17, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,804 | $45.25 | $81,631.00 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,773,461 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.85 to 45.70, inclusive. Read SEC document |
| March 17, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,295 | $44.03 | $57,018.85 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,775,265 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $43.67 to 44.52, inclusive. Read SEC document |
| March 17, 2021 Filed Mar 20, 2021 01:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 1,901 | $43.22 | $82,161.22 |
DisclosureSEC source: 0001209191-21-022204 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,776,560 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $42.64 to 43.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 17, 2021 Filed Mar 20, 2021 01:00 UTC |
Trigg LeslieDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,109 | $0.00 Strike: $45.01 | $0.00 |
DisclosureSEC source: 0001209191-21-022203 · doc4.xml · derivative · entry 2 Trigg Leslie · CIK 0001304125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,109 Underlying: Common Stock · 11,109 shares Expires 2031-03-17 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 17, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 17, 2021 Filed Mar 20, 2021 01:00 UTC |
Trigg LeslieDirector
|
GrantCommon Stock | 4,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022203 · doc4.xml · nonDerivative · entry 1 Trigg Leslie · CIK 0001304125 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Read SEC document |
| March 17, 2021 Filed Mar 22, 2021 15:54 UTC |
OWEN KATEY EINTERZDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,109 | $0.00 Strike: $45.01 | $0.00 |
DisclosureSEC source: 0001209191-21-022231 · doc4.xml · derivative · entry 2 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,109 Underlying: Common Stock · 11,109 shares Expires 2031-03-17 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 17, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 17, 2021 Filed Mar 22, 2021 15:54 UTC |
OWEN KATEY EINTERZDirector
|
GrantCommon Stock | 4,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022231 · doc4.xml · nonDerivative · entry 1 OWEN KATEY EINTERZ · CIK 0001852578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-021550 · doc4.xml · derivative · entry 7 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 1,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 1,500 | $47.00 | $70,500.00 |
DisclosureSEC source: 0001209191-21-021550 · doc4.xml · nonDerivative · entry 5 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 1,500 | $7.80 | $11,700.00 |
DisclosureSEC source: 0001209191-21-021550 · doc4.xml · nonDerivative · entry 4 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 2,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-021549 · doc4.xml · derivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 2,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 1,122 | $42.03 | $47,157.66 |
DisclosureSEC source: 0001209191-21-021549 · doc4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.942 to 42.28, inclusive. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
LO FRANCISChief People Officer
|
SaleCommon Stock | 878 | $41.57 | $36,498.46 |
DisclosureSEC source: 0001209191-21-021549 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,726 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.95 to 41.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
LO FRANCISChief People Officer
|
Exercise / conversionCommon Stock | 2,000 | $7.80 | $15,600.00 |
DisclosureSEC source: 0001209191-21-021549 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-021550 · doc4.xml · derivative · entry 6 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,500 Underlying: Common Stock · 4,500 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 28, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 3,609 | $41.89 | $151,181.01 |
DisclosureSEC source: 0001209191-21-021550 · doc4.xml · nonDerivative · entry 3 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,504 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.51 to 42.23, inclusive. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
SaleCommon Stock | 891 | $41.17 | $36,682.47 |
DisclosureSEC source: 0001209191-21-021550 · doc4.xml · nonDerivative · entry 2 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,113 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.51 to 41.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
GRIFFIN MICHELLE RENEEDirector
|
Exercise / conversionCommon Stock | 4,500 | $7.80 | $35,100.00 |
DisclosureSEC source: 0001209191-21-021550 · doc4.xml · nonDerivative · entry 1 GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2020. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 23:00 UTC |
BENZENO SHARONChief Business Development Off
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,354 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-21-021548 · doc4.xml · derivative · entry 4 BENZENO SHARON · CIK 0001780854 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,396 Underlying: Common Stock · 1,354 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.